Medtronic plc (MDT)
| Market Cap | 104.14B |
| Revenue (ttm) | 33.54B |
| Net Income (ttm) | 4.66B |
| Shares Out | 1.28B |
| EPS (ttm) | 3.61 |
| PE Ratio | 22.50 |
| Forward PE | 14.64 |
| Dividend | $2.84 (3.50%) |
| Ex-Dividend Date | Jun 27, 2025 |
| Volume | 7,515,636 |
| Open | 81.50 |
| Previous Close | 81.18 |
| Day's Range | 81.14 - 82.30 |
| 52-Week Range | 75.96 - 96.25 |
| Beta | 0.83 |
| Analysts | Hold |
| Price Target | 94.73 (+16.61%) |
| Earnings Date | May 21, 2025 |
About MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accesso... [Read more]
Financial Performance
In 2025, Medtronic's revenue was $33.54 billion, an increase of 3.62% compared to the previous year's $32.36 billion. Earnings were $4.66 billion, an increase of 26.82%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for MDT stock is "Hold." The 12-month stock price forecast is $94.73, which is an increase of 16.61% from the latest price.
News
No Rolex For Me - I'm Buying Dividends That Pay For Life
I love luxury watches, but buying more to "earn" access to rarer models made me realize how easy it is to waste capital chasing ego-driven goals. Unlike watches, dividend growth stocks offer reliable ...
Medtronic: Diabetes Spin-Off Is Near-Term Catalyst; Rating Upgrade
Upgrading Medtronic to 'Strong Buy' with a $104 fair value, driven by the diabetes business spin-off catalyst. Divesting diabetes enables Medtronic to focus on core cardiac and surgical markets, impro...
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference
GALWAY, Ireland , May 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions Conferen...
'WIN-WIN': Medtronic CEO explains the reason for diabetes biz spin
Medtronic chairman and CEO Geoff Martha explains why the company is separating the diabetes business on 'The Claman Countdown.' #foxbusiness #usnews #economy #investing #diabetes #health #markets
Medtronic plc (MDT) Q4 2025 Earnings Call Transcript
Medtronic plc (NYSE:MDT) Q4 2025 Earnings Conference Call May 21, 2025 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head of IR Geoff Martha - Chairman and CEO Que Dallara - EVP & Presid...
Medtronic CEO: More companies are spinning off problems, we're spinning off an attractive asset
Geoff Martha, Medtronic CEO, joins 'Money Movers' to discuss the company's spinoff plans, growth strategy and surgical robotics.
Medtronic to split off its fast-growing diabetes business to unlock its value
The new diabetes company will be predominantly business-to-consumer, while Medtronic's model was more business-to-business.
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase
Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland , May 21, 2025 /PRNewswire/ -- Medtronic plc ...
Medtronic announces intent to separate Diabetes business
Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only com...
Medtronic to separate diabetes business, WSJ reports
Medical device maker Medtronic plans to separate its diabetes business into a stand-alone company, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Medtronic to Separate Diabetes Business
The medical device maker has been working to turn around the division over the last few years.
Will Medtronic's Earnings Move The Stock?
Medtronic (NYSE:MDT) is scheduled to announce its earnings on Wednesday, May 21, 2025. Over the last five years, Medtronic's stock has shown a favorable one-day return following its earnings announcem...
Trump tariff 'tornado' still hunting markets: Former Medtronic CEO
You can catch Opening Bid on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. There has been one common theme from Corporate America throughout the last two months as the Trump adm...
Medtronic: Quite A Few Supportive Sub-Plots Ahead Of The Q4-25 Earnings
Medtronic has outperformed the S&P500 and other healthcare stocks from the S&P500 this year, but now faces a pivotal earnings event on the 21st of May. Cardiovascular portfolio strength, especially fr...
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025
GALWAY, Ireland , May 7, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full...
New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women
Star Jones, award winning television personality & women's heart health advocate, helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign GALWAY, ...
Smart Pills Market Industry Trend Analysis, and Forecast 2025-2034, with Profiles of ANX Robotica, Bodycap, CapsoVision, Check-Cap, etectRx, Intromedic, Medtronic, Otsuka, Olympus and RF
Key growth drivers include the rise of gastrointestinal disorders and demand for non-invasive diagnostics. Smart pills, equipped with sensors and AI, facilitate real-time monitoring and personalized m...
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed...
Medtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients
One-year clinical trial data for the next-generation, investigational, Sphere-360™ single-shot PFA catheter show impressive safety, performance, and efficiency results for paroxysmal Afib Dual-energy ...
Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system
Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic surgery in the U.S. presented as a late-breaker at the American Urologic Associat...
Medtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure™ lead and announces investigational clinical study results
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: Late-b...
Medtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump
GALWAY, Ireland , April 24, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has submitted 510(k) applications to the U.S. Food and Drug Adm...
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
FDA recently granted Breakthrough Device Designation to AVIM therapy for use in patients with uncontrolled hypertension at increased cardiovascular risk HRS Satellite Symposium will feature leading ex...
Medtronic: Time To Buy This Dividend Aristocrat Bargain
In recent months, Medtronic has soundly outperformed the S&P 500 index. The company's recent regulatory approvals should bode well for non-GAAP EPS growth in the coming years. Medtronic's interest cov...
Medtronic: One Of The Best Times To Buy
Medtronic offers a compelling long-term investment opportunity with solid revenue and earnings growth, driven by innovation in the cardiovascular, neuromodulation, and diabetes care segments. Medtroni...